# A Phase 1 Trial of KAN-001 With Pembrolizumab, With or Without Chemotherapy, in Participants With PD-L1-Positive Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07910942/  
OnCo record `nct07910942` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of KAN-001 run by Kanvas Biosciences, not yet recruiting.

## Summary

A Phase 1 Trial of KAN-001 With Pembrolizumab, With or Without Chemotherapy, in Participants With PD-L1-Positive Non-Small Cell Lung Cancer is a phase 1 interventional study registered as NCT07910942 by Kanvas Biosciences, with 40 participants planned, started 2026-11. Conditions recorded: Non-Small Cell Lung Cancer. Interventions recorded: KAN-001 and Pembrolizumab.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07910942
- Phase: 1
- Setting: A Phase 1 Trial to Evaluate Safety, Tolerability, and Engraftment of KAN-001 in Combination With Pembrolizumab, With or Without Chemotherapy, in Participants With PD-L1-Positive Non-Small Cell Lung Cancer
- Sponsor: Kanvas Biosciences
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT07910942: https://clinicaltrials.gov/study/NCT07910942

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [KAN-001](https://onco.cc/drugs/kan-001/)
- companies: [Kanvas Biosciences](https://onco.cc/companies/kanvas-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct07910942.json